U.S. Application No.: New Application (Divisional of U.S. Application No. 10/435,354) Preliminary Amendment

## IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1 - 23. canceled

- 24. (newly added): A pharmaceutical composition comprising a corticosteroid, a propellant, a cosolvent, and an antioxidant.
- 25. (newly added): The pharmaceutical composition of claim 24,wherein said antioxidant is ascorbyl palmitate.
- 26. (newly added): The pharmaceutical composition of claim 24, wherein said antioxidant is tocopherol.
- 27. (newly added): The pharmaceutical composition of claim 24, wherein said antioxidant is selected from the group consisting of ascorbic acid, ascorbyl palmitate, butylated hydroxytoluene, butylated hydroxyanisole, and tocopherol.
- 28. (newly added): The pharmaceutical composition of claim 24, wherein the corticosteroid is selected from the group consisting of flunisolide and beclomethasone dipropionate.

- U.S. Application No.: New Application (Divisional of U.S. Application No. 10/435,354) Preliminary Amendment
- 29. (newly added): The pharmaceutical composition of claim 24, wherein the propellant is 1,1,1,2- tetrafluoroethane, 1,1,1,2,3,3,3- heptafluoropropane, or a mixture thereof.
- 30. (newly added): The pharmaceutical composition of claim 24, wherein said cosolvent is an alcohol.
- 31. (newly added): The pharmaceutical composition of claim 30, wherein said alcohol is ethanol.
- 32. (newly added): A pressurized metered dose inhaler comprising a container equipped with a metering valve and containing a pressurized aerosol formulation comprising a corticosteroid, a propellant, a cosolvent, and an antioxidant.
- 33. (newly added): The pressurized metered dose inhaler according to claim 32, wherein the corticosteroid is selected from the group consisting of flunisolide and beclomethasone dipropionate.
- 34. (newly added): The pressurized metered dose inhaler according to claim 32, wherein said propellant is 1,1,1,2- tetrafluoroethane, 1,1,1,2,3,3,3- heptafluoropropane, or a mixture thereof.
  - 35. (newly added): The pressurized metered dose inhaler according to claim 32,

U.S. Application No.: New Application (Divisional of U.S. Application No. 10/435,354) Preliminary Amendment

wherein said cosolvent is an alcohol.

- 36. (newly added): The pressurized metered dose inhaler according to claim 35, wherein said alcohol is ethanol.
- 37. (newly added): The pressurized metered dose inhaler according to claim 32, wherein said antioxidant is ascorbyl palmitate.
- 38. (newly added): The pressurized metered dose inhaler according to claim 32, wherein said antioxidant is tocopherol.
- 39. (newly added): A method for the treatment of a bronchial disorder comprising administering a pharmaceutical formulation comprising a corticosteroid, a propellant, a cosolvent, and an antioxidant.
- 40. (newly added): The method according to claim 39, wherein said corticosteroid is selected from the group consisting of flunisolide and beclomethasone dipropionate.
- 41. (newly added): The method according to claim 40, wherein said propellant is 1,1,1,2- tetrafluoroethane, 1,1,1,2,3,3,3- heptafluoropropane or a mixture thereof.
- 42. (newly added): The method according to claim 40, wherein said cosolvent is an alcohol.

- U.S. Application No.: New Application (Divisional of U.S. Application No. 10/435,354) Preliminary Amendment
  - 43. (newly added): The method according to claim 42, wherein said alcohol is ethanol.
  - 44. (newly added): The method according to claim 40, wherein said antioxidant is ascorbyl palmitate.
  - 45. (newly added): The method according to claim 40, wherein said antioxidant is tocopherol.

U.S. Application No.: New Application (Divisional of U.S. Application No. 10/435,354) Preliminary Amendment

## SUPPORT FOR THE AMENDMENTS

Applicants have canceled Claims 1-23 and added new Claims 24-45.

Claim 24 is supported by page 1, lines 1-18; page 12, line 29, to page 13, line 8; and original Claim 1;

Claim 25 is supported by page 12, line 29, to page 13, line 8;

Claim 26 is supported by page 12, line 29, to page 13, line 8;

Claim 27 is supported by page 12, line 29, to page 13, line 8;

Claim 28 is supported by page 14, lines 16-22; and page 18, lines 25-29;

Claim 29 is supported by page 2, line 27, to page 3, line 1; and original Claim 9;

Claim 30 is supported by page 12, lines 6-8;

Claim 31 is supported by page 12, lines 6-8;

Claim 32 is supported by page 1, lines 1-18; page 12, line 29, to page 13, line 8; and original Claim 1;

Claim 33 is supported by page 14, lines 16-22; and page 18, lines 25-29;

Claim 34 is supported by page 2, line 27, to page 3, line 1; and original Claim 9;

Claim 35 is supported by page 12, lines 6-8;

Claim 36 is supported by page 12, lines 6-8;

Claim 37 is supported by page 12, line 29, to page 13, line 8;

Claim 38 is supported by page 12, line 29, to page 13, line 8;

Claim 39 is supported by page 1, lines 1-18; page 12, line 29, to page 13, line 8; and original Claim 1;

Claim 40 is supported by page 14, lines 16-22; and page 18, lines 25-29;

Claim 41 is supported by page 2, line 27, to page 3, line 1; and original Claim 9;